The Effects of FR-167653 on Postoperative Intimal Hyperplasia of the Interposition Vein Graft in Rat: 2nd Report

(Department of Cardiovascular Surgery, Hyogo College of Medicine, Nishinomiya, Japan)

Mitsuhiro Yamamura Hideki Yao Takashi Miyamoto
Recently we reported that the inhibitor of p38 mitogen-activated protein kinase, FR-167653 (Fujisawa Pharm. Co., Ltd., Osaka) may suppress postoperative intimal hyperplasia. In this study we evaluated the best dosage and phase for administration of FR-167653, in order to clarify its mechanism in the postoperative treatment of intimal hyperplasia. Twenty-one Lewis male rats (484}5g) were studied. The epigastric vein graft was interposed into the common femoral artery. The rats were divided into four groups according to the dosage and phase of administration of FR-167653: group I (n5) with 2.0ƒĘg/g of FR-167653 immediately before bypass, group T (n5) with 2.0ƒĘg/g immediately before bypass and 2 weeks after bypass, group D (n5) with 4.0ƒĘg/g immediately before bypass, and the control group (n6) with the same dose of saline. The intimal areas of vein grafts were measured at 4 weeks postoperatively. The mean intimal areas in group I, T and D were significantly decreased compared with the control group, especially in group D (0.05}0.02mm2 vs. 0.43}0.05mm2, pƒ0.001). These results suggest that FR-167653 can suppress the postoperative intimal hyperplasia that occurs with interposition of vein grafts in rats.
@Jpn. J. Cardiovasc. Surg. 32F75 -78i2003)